MammaPrint Breast Cancer Test Shown To Be Powerful Tool

Armen Hareyan's picture
Advertisement

Agendia BV's MammaPrint breast cancer prognosis test was shown to be a valuable tool to assess risk of breast cancer recurrence also in post menopausal breast cancer patients. Data recently presented at the AACR/NCI/ EORTC conference "Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications" in San Francisco showed that MammaPrint is a valuable tool to assess risk of breast cancer recurrence in older age breast cancer patients as well.

To date, MammaPrint has received two clearances from the Food and Drug Administration (FDA) for its test. The first clearance in February of this year cleared MammaPrint for safety and effectiveness under the In Vitro Diagnostic Multivariate Index Assay (IVDMIA) Guidelines for use in breast cancer prognosis. In June, Agendia received a second clearance for the test in conjunction with RNARetain, an RNA stabilizing solution allowing shipping of tumor biopsies at ambient temperature, greatly facilitating the logistical process of sample handling. FDA clearance also ensures the validity of the RNA integrity chain from patient to result, which ensures that the whole test procedure is fit for daily clinical settings. With the

Advertisement